Effect of Flozin (dapagliflozin) Administration on Myocardial and Peripheral Vascular Remodeling
NCT06679179 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2024-11-07
Summary
The aim of this study is to assess the effect of treatment with flozin (dapagliflozin 10mg once a day) on haemodynamic parameters and myocardial and peripheral vascular remodeling in patients with NYHA class II-III heart failure.
Conditions
Sponsors & Collaborators
-
Poznan University of Medical Sciences
lead OTHER
Principal Investigators
-
Arkadiusz Niklas, PhD · University Clinical Hospital in Poznań, 49 Przybyszewskiego Street, 60-355 Poznań
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-10
- Primary Completion
- 2026-02-28
- Completion
- 2026-02-28
Countries
- Poland
Study Locations
More Related Trials
-
Use of Flozins (Empagliflozin/Dapagliflozin) for Prevention of AKI
NCT07231939 ·Status: RECRUITING
-
Empagliflozin in Hypertrophic Cardiomyopathy
NCT05182658 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
NCT04956809 ·Status: COMPLETED ·Phase: PHASE2
-
Impact on Atrial Remodeling of Dapaglifozin in Patients With Heart Failure .
NCT04707352 ·Status: COMPLETED ·Phase: PHASE3
-
Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction
NCT06046612 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
NCT06307652 ·Status: RECRUITING ·Phase: PHASE3
-
Levosimendan In Ambulatory Heart Failure Patients
NCT04705337 ·Status: TERMINATED ·Phase: PHASE4
-
Dapagliflozin Effect on Symptoms and Biomarkers in Patients With Heart Failure
NCT02653482 ·Status: COMPLETED ·Phase: PHASE4
-
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
NCT03619213 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Research : Assessment of Effect of Combination of Drugs in the Treatment of Heart Failure
NCT06158711 ·Status: NOT_YET_RECRUITING
-
Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
NCT03271879 ·Status: UNKNOWN ·Phase: PHASE4
-
Dapagliflozin Effect on FunctiOnal Mitral Regurgitation and Myocardial Remodeling
NCT05606718 ·Status: UNKNOWN ·Phase: PHASE4
-
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
NCT03448419 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
NCT03036124 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Dapagliflozin on VT in Patients With Heart Failure.
NCT05550441 ·Status: UNKNOWN ·Phase: PHASE4
-
Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus
NCT06632561 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of a Repetitive Use of 24-hour Levosimendan Infusions in Patients With Severe Systolic Heart Failure in Order to Prevent Rehospitalizations
NCT03764722 ·Status: UNKNOWN ·Phase: PHASE4
-
Effect of Intravenous FerRic carbOxymaltose oN Reverse Remodeling Following Cardiac Resynchronization Therapy
NCT03380520 ·Status: COMPLETED ·Phase: PHASE4
-
Dapagliflozin in the Treatment of Heart Failure
NCT05727423 ·Status: ACTIVE_NOT_RECRUITING
-
Determination of Drug Levels for Pharmacotherapy of Heart Failure
NCT06035978 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Dapagliflozin in PRESERVED Ejection Fraction Heart Failure
NCT03030235 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Dapagliflozin on Recurrence After Catheter Ablation for Atrial Fibrillation
NCT06433479 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department
NCT06683053 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
NCT05764057 ·Status: RECRUITING ·Phase: PHASE3
-
Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
NCT06759909 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1